股本结构
单位：万股
| 公告日期 | 2025-12-05 | 2025-12-05 | 2025-11-19 | 2025-11-19 | 2025-08-08 | 2025-08-08 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1072.97 | 982.97 | 820.97 | 743.29 | 702.10 | 667.91 |
| 普通股本 | 1072.97 | 982.97 | 820.97 | 743.29 | 702.10 | 667.91 |
| 优先股 | 未披露 | 未披露 | 未披露 | 6.74 | 未披露 | 7.48 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-12-05 | 2025-12-01 | 2025-11-18 | 2025-09-30 | 2025-08-07 | 2025-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-12-05 | 1072.97 | 未披露 |
更多>>
Common Stock offered 900,000 shares by the company
|
2025-12-05 |
| 2025-12-05 | 982.97 | 未披露 | 定期报告 | 2025-12-01 |
| 2025-11-19 | 820.97 | 未披露 | 定期报告 | 2025-11-18 |
| 2025-11-19 | 743.29 | 6.74 |
更多>>
From June 30,2025 to September 30,2025
Exercise of stock options
Issuance of common stock under employee stock purchase plan
Conversion of Preferred Stock
|
2025-09-30 |
| 2025-08-08 | 702.10 | 未披露 | 定期报告 | 2025-08-07 |
| 2025-08-08 | 667.91 | 7.48 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock for vested restricted stock units
|
2025-06-30 |
| 2025-05-14 | 645.24 | 7.78 |
更多>>
From December 31, 2024 to March 31, 2025
Conversion of Series H Preferred Stock
Issuance of common stock for vested restricted stock units
Issuance of common stock under employee stock purchase plan
|
2025-03-31 |
| 2025-03-31 | 645.24 | 未披露 | 定期报告 | 2025-03-01 |
| 2025-03-31 | 609.12 | 7.78 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of convertible Series G preferred stock, net of issuance cost of $62
Issuance of convertible Series H preferred stock, net of issuance cost of $96
Issuance of convertible Series I preferred stock, net of issuance cost of $24
At the market offering, net of offering costs of $69
Exercise of stock options
Issuance of common stock for vested restricted stock units
Issuance of common stock under employee stock purchase plan
Issuance of common stock to satisfy service contract
Issuance of common stock, net of issuance costs of $218
|
2024-12-31 |
| 2024-12-30 | 475.06 | 未披露 | 定期报告 | 2024-12-27 |
| 2024-11-12 | 461.01 | 7.45 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock under employee stock purchase plan
Issuance of common stock for vested restricted stock units
Exercise of stock options
|
2024-09-30 |
| 2024-08-06 | 460.76 | 未披露 | 定期报告 | 2024-08-05 |
| 2024-08-06 | 459.84 | 7.45 |
更多>>
From March 31, 2024 to June 30, 2024
Common stock offering, net of offering costs of $122
At the market offering, net of offering costs of $50
Issuance of common stock for vested restricted stock units
Issuance of convertible Series H preferred stock, net of issuance cost of $96
|
2024-06-30 |
| 2024-06-27 | 445.89 | 未披露 |
更多>>
KALA BIO, Inc. Expects to have 4,458,909 shares of Common Stock outstanding, as of June 28, 2024 and after giving effect to the 1,197,314 shares of Common Stock to be issued and sold in the Private Placement.
|
2024-06-28 |
| 2024-06-27 | 326.16 | 未披露 | 定期报告 | 2024-06-26 |
| 2024-05-14 | 281.65 | 6.51 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of convertible Series G preferred stock, net of issuance cost of $62
Issuance of common stock for vested restricted stock units
Issuance of common stock under employee stock purchase plan
Issuance of common stock to satisfy service contract
|
2024-03-31 |
| 2024-03-29 | 281.65 | 未披露 | 定期报告 | 2024-03-28 |
| 2024-03-29 | 275.94 | 5.42 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of common stock upon conversion of Series E Preferred Stock
|
2023-12-31 |
| 2023-11-13 | 269.31 | 5.12 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock upon conversion of Series E Preferred Stock
|
2023-09-30 |
| 2023-08-04 | 254.27 | 未披露 | 定期报告 | 2023-08-03 |
| 2023-08-04 | 253.87 | 5.28 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock upon conversion of Series E Preferred Stock
|
2023-06-30 |
| 2023-05-09 | 234.87 | 未披露 | 定期报告 | 2023-05-08 |
| 2023-05-09 | 230.93 | 5.31 |
更多>>
From December 31, 2022 to March 31, 2023
At the market offering, net of offering costs of $384
Issuance of common stock for vested restricted stock units
Issuance of common stock under employee stock purchase plan
Issuance of common stock to satisfy deferred purchase consideration
Issuance of common stock to satisfy contingent consideration
|
2023-03-31 |
| 2023-03-13 | 202.55 | 未披露 | 定期报告 | 2023-02-24 |
| 2023-03-03 | 170.70 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of convertible Series E preferred stock upon settlement of Second Closing Right, net of issuance costs of $194
Issuance of convertible Series E preferred stock and Second Closing Right, net of issuance costs of $43
Redemption of redeemable Series D preferred stock
Issuance of redeemable Series D preferred stock
|
2022-12-31 |
| 2022-11-08 | 151.84 | 未披露 | 定期报告 | 2022-11-07 |
| 2022-10-20 | 146.42 | 未披露 |
更多>>
Kala Pharmaceuticals, Inc. announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.
|
2022-10-21 |
| 2022-09-09 | 7320.81 | 7.32 | 定期报告 | 2022-08-31 |
| 2022-08-11 | 7320.81 | 未披露 | 定期报告 | 2022-08-10 |
| 2022-08-11 | 7267.38 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock for vested restricted stock units
|
2022-06-30 |
| 2022-03-29 | 7259.40 | 未披露 | 定期报告 | 2022-03-28 |
| 2021-11-15 | 6550.03 | 未披露 | 定期报告 | 2021-11-12 |
| 2021-11-15 | 6508.52 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
At the market offering, net of offering costs of $9
Issuance of common stock under employee stock purchase plan
|
2021-09-30 |
| 2021-08-05 | 6497.11 | 未披露 | 定期报告 | 2021-08-04 |
| 2021-08-05 | 6477.02 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
At the market offering, net of sales agent commission of $170
Exercise of stock options
Issuance of vested restricted stock units
|
2021-06-30 |
| 2021-05-05 | 6464.24 | 未披露 | 定期报告 | 2021-05-04 |
| 2021-04-28 | 6458.25 | 未披露 | 定期报告 | 2021-04-21 |
| 2021-05-05 | 6380.51 | 未披露 |
更多>>
from December 31, 2020 to March 31, 2021
Exercise of stock options
Issuance under employee stock purchase plan
At the market offering, net of sales agent commission of $991
|
2021-03-31 |
| 2021-02-25 | 6155.24 | 未披露 | 定期报告 | 2021-02-24 |
| 2021-02-25 | 5891.54 | 未披露 |
更多>>
From December 31,2019 to December 31,2020
Issuance under employee stock purchase plan
Exercise of stock options
At the market offering, net of offering costs $1,026,000
Common stock offering, net of offering costs of $8,475,000
Warrant exercises
|
2020-12-31 |
| 2020-11-05 | 5607.52 | 未披露 | 定期报告 | 2020-11-04 |
| 2020-11-05 | 5606.14 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance under employee stock purchase plan
Exercise of stock options
|
2020-09-30 |
| 2020-08-06 | 5605.99 | 未披露 | 定期报告 | 2020-08-03 |
| 2020-08-06 | 5583.10 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Exercise of stock options
Common stock offering, net of issuance cost and underwriting fees of $0.5 million
Warrant exercises
|
2020-06-30 |
| 2020-04-29 | 5571.59 | 未披露 | 定期报告 | 2020-04-27 |
| 2020-04-29 | 5568.88 | 未披露 | 定期报告 | 2020-04-20 |
| 2020-05-07 | 5458.56 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
At the market offering, net of sales agent commission of $0.4 million
Exercise of stock options
Common stock offering, net of issuance cost and underwriting fees of $8.1 million
Issuance under employee stock purchase plan
|
2020-03-31 |
| 2020-03-13 | 5457.30 | 未披露 |
更多>>
1.Common stock offered by us 16,000,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on the 38,573,034 shares of our common stock outstanding as of March 2, 2020.
|
2020-03-13 |
| 2020-03-11 | 3857.30 | 未披露 | 定期报告 | 2020-03-02 |
| 2020-02-12 | 3680.39 | 未披露 | 定期报告 | 2020-02-10 |
| 2020-02-12 | 3608.63 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
At the market offering, net of sales agent commission and fees of $0.3 million
Exercise of stock options
Issuance under employee stock purchase plan
|
2019-12-31 |
| 2019-11-07 | 3454.38 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
At the market offering, net of sales agent commission of $0.1 million
Exercise of stock options
Issuance under employee stock purchase plan
|
2019-09-30 |
| 2019-08-06 | 3400.66 | 未披露 | 定期报告 | 2019-08-02 |
| 2019-08-06 | 3388.30 | 未披露 |
更多>>
from December 31, 2018 to June 30, 2019
Exercise of stock options
|
2019-06-30 |
| 2019-05-09 | 3388.29 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Exercise of stock options
|
2019-03-31 |
| 2019-03-12 | 3388.29 | 未披露 | 定期报告 | 2019-03-06 |
| 2019-03-12 | 3386.31 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Common stock Offering, net of issuance cost and underwriting fees of $5.0 million
At-the-market offering, net of sales agent commission of $0.1 million
Exercise of stock options
|
2018-12-31 |
| 2018-11-08 | 3379.57 | 未披露 | 定期报告 | 2018-11-06 |
| 2018-11-08 | 2464.55 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-09 | 2459.23 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-10 | 2456.24 | 未披露 | 定期报告 | 2018-05-09 |
| 2018-05-10 | 2455.61 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-04-02 | 2455.61 | 未披露 | 定期报告 | 2018-03-26 |
| 2018-04-02 | 2453.83 | 未披露 |
更多>>
From December 31, 2016 to December 31, 2017
Conversion of preferred stock upon IPO
Issuance of common stock upon IPO, net of underwriters discount and offering costs of $9,495
Exercise of warrants
Exercise of stock options
|
2017-12-31 |
| 2017-11-07 | 2452.11 | 未披露 | 定期报告 | 2017-10-31 |
| 2017-11-07 | 2434.72 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-31 | 2422.71 | 未披露 |
更多>>
On July 7, 2017, the Company effected a one-for-5.2083 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company’s Convertible Preferred Stock.
|
2017-07-31 |
| 2017-07-20 | 2328.34 | 未披露 | 定期报告 | 2017-07-20 |
| 2017-08-31 | 118.14 | 8386.40 | 定期报告 | 2017-06-30 |
| 2017-06-23 | 615.33 | 8386.40 |
更多>>
from December 31, 2015 to December 31, 2016
Issuance of Series C preferred stock-net of issuance costs of $402
|
2016-12-31 |
Common Stock offered 900,000 shares by the company
From June 30,2025 to September 30,2025
Exercise of stock options
Issuance of common stock under employee stock purchase plan
Conversion of Preferred Stock
From March 31, 2025 to June 30, 2025
Issuance of common stock for vested restricted stock units
From December 31, 2024 to March 31, 2025
Conversion of Series H Preferred Stock
Issuance of common stock for vested restricted stock units
Issuance of common stock under employee stock purchase plan
From December 31, 2023 to December 31, 2024
Issuance of convertible Series G preferred stock, net of issuance cost of $62
Issuance of convertible Series H preferred stock, net of issuance cost of $96
Issuance of convertible Series I preferred stock, net of issuance cost of $24
At the market offering, net of offering costs of $69
Exercise of stock options
Issuance of common stock for vested restricted stock units
Issuance of common stock under employee stock purchase plan
Issuance of common stock to satisfy service contract
Issuance of common stock, net of issuance costs of $218
From June 30, 2024 to September 30, 2024
Issuance of common stock under employee stock purchase plan
Issuance of common stock for vested restricted stock units
Exercise of stock options
From March 31, 2024 to June 30, 2024
Common stock offering, net of offering costs of $122
At the market offering, net of offering costs of $50
Issuance of common stock for vested restricted stock units
Issuance of convertible Series H preferred stock, net of issuance cost of $96
KALA BIO, Inc. Expects to have 4,458,909 shares of Common Stock outstanding, as of June 28, 2024 and after giving effect to the 1,197,314 shares of Common Stock to be issued and sold in the Private Placement.
From December 31, 2023 to March 31, 2024
Issuance of convertible Series G preferred stock, net of issuance cost of $62
Issuance of common stock for vested restricted stock units
Issuance of common stock under employee stock purchase plan
Issuance of common stock to satisfy service contract
From December 31, 2022 to December 31, 2023
Issuance of common stock upon conversion of Series E Preferred Stock
From June 30, 2023 to September 30, 2023
Issuance of common stock upon conversion of Series E Preferred Stock
From March 31, 2023 to June 30, 2023
Issuance of common stock upon conversion of Series E Preferred Stock
From December 31, 2022 to March 31, 2023
At the market offering, net of offering costs of $384
Issuance of common stock for vested restricted stock units
Issuance of common stock under employee stock purchase plan
Issuance of common stock to satisfy deferred purchase consideration
Issuance of common stock to satisfy contingent consideration
From December 31, 2021 to December 31, 2022
Issuance of convertible Series E preferred stock upon settlement of Second Closing Right, net of issuance costs of $194
Issuance of convertible Series E preferred stock and Second Closing Right, net of issuance costs of $43
Redemption of redeemable Series D preferred stock
Issuance of redeemable Series D preferred stock
Kala Pharmaceuticals, Inc. announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.
From March 31, 2022 to June 30, 2022
Issuance of common stock for vested restricted stock units
From June 30, 2021 to September 30, 2021
At the market offering, net of offering costs of $9
Issuance of common stock under employee stock purchase plan
From March 31, 2021 to June 30, 2021
At the market offering, net of sales agent commission of $170
Exercise of stock options
Issuance of vested restricted stock units
from December 31, 2020 to March 31, 2021
Exercise of stock options
Issuance under employee stock purchase plan
At the market offering, net of sales agent commission of $991
From December 31,2019 to December 31,2020
Issuance under employee stock purchase plan
Exercise of stock options
At the market offering, net of offering costs $1,026,000
Common stock offering, net of offering costs of $8,475,000
Warrant exercises
From June 30, 2020 to September 30, 2020
Issuance under employee stock purchase plan
Exercise of stock options
From March 31, 2020 to June 30, 2020
Exercise of stock options
Common stock offering, net of issuance cost and underwriting fees of $0.5 million
Warrant exercises
From December 31, 2019 to March 31, 2020
At the market offering, net of sales agent commission of $0.4 million
Exercise of stock options
Common stock offering, net of issuance cost and underwriting fees of $8.1 million
Issuance under employee stock purchase plan
1.Common stock offered by us 16,000,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on the 38,573,034 shares of our common stock outstanding as of March 2, 2020.
from December 31, 2018 to December 31, 2019
At the market offering, net of sales agent commission and fees of $0.3 million
Exercise of stock options
Issuance under employee stock purchase plan
from June 30, 2019 to September 30, 2019
At the market offering, net of sales agent commission of $0.1 million
Exercise of stock options
Issuance under employee stock purchase plan
from December 31, 2018 to June 30, 2019
Exercise of stock options
from December 31, 2018 to March 31, 2019
Exercise of stock options
from December 31, 2017 to December 31, 2018
Common stock Offering, net of issuance cost and underwriting fees of $5.0 million
At-the-market offering, net of sales agent commission of $0.1 million
Exercise of stock options
From December 31, 2016 to December 31, 2017
Conversion of preferred stock upon IPO
Issuance of common stock upon IPO, net of underwriters discount and offering costs of $9,495
Exercise of warrants
Exercise of stock options
On July 7, 2017, the Company effected a one-for-5.2083 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company’s Convertible Preferred Stock.
from December 31, 2015 to December 31, 2016
Issuance of Series C preferred stock-net of issuance costs of $402